Study guide
13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
CBCN Certified Breast Care Nurse Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CBCN Exam
CBCN Exam Facts, 2026 Blueprint & Study Plan
2 Chapter 1: Breast Health, Examination & Benign Conditions (Care Continuum)
1.1 Breast Anatomy, Vascular Supply & Hormonal Physiology 1.2 Clinical Breast Examination & Breast Awareness Education 1.3 Benign Breast Conditions, Mastalgia & Fibrocystic Changes
3 Chapter 2: Screening, Breast Density & Special Populations (Care Continuum)
2.1 Screening Modalities, Breast Density & Pharmacologic Risk Reduction 2.2 Screening & Breast Health in Special Populations
4 Chapter 3: Cancer Risk Assessment & Genetics (Care Continuum)
3.1 Proliferative Lesions, Atypia & High-Risk Benign Pathology 3.2 Breast Cancer Risk Models (Gail, Tyrer-Cuzick, Claus, BRCAPRO) 3.3 Hereditary Cancer Syndromes & Genetic Evaluation
5 Chapter 4: Patient Navigation, Surveillance & Survivorship (Care Continuum)
4.1 Patient Navigation, Barriers to Care, Social Determinants & Interprofessional Collaboration 4.2 Survivorship Care Planning, Surveillance Intervals & Recurrence Monitoring 4.3 Secondary Prevention, Physical Activity, Nutrition & Wellness Guidance
6 Chapter 5: Carcinogenesis & Diagnostic Evaluation (Diagnosis and Staging)
5.1 Carcinogenesis: How Breast Cancer Develops and Spreads 5.2 Clinical Assessment, Diagnostic Imaging & BI-RADS Categorization 5.3 Breast Biopsy Modalities & Image-Guided Localization Techniques
7 Chapter 6: Pathology, Biomarkers & Genomic Testing (Diagnosis and Staging)
6.1 Histopathology: In Situ Carcinomas & Invasive Carcinoma Subtypes 6.2 Receptor Biomarkers (ER, PR, HER2, Ki-67) & Molecular Subtypes 6.3 Multigene Genomic Assays & Recurrence Risk Stratification
8 Chapter 7: Clinical & Pathologic Staging (Diagnosis and Staging)
7.1 AJCC TNM Staging System (Anatomic vs Prognostic Staging) 7.2 Staging Workup: When to Use MRI, CT, Bone Scan & PET
9 Chapter 8: Breast Surgery, Axillary Staging & Reconstruction (Treatment Modalities)
8.1 Breast-Conserving Surgery, Margin Standards & Mastectomy Techniques 8.2 Axillary Staging: Sentinel Lymph Node Biopsy vs. Axillary Dissection 8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery
10 Chapter 9: Radiation Therapy & Chemotherapy (Treatment Modalities)
9.1 Radiation Therapy: Whole Breast, Chest Wall, Regional Nodal & Partial Breast Irradiation 9.2 Neoadjuvant vs. Adjuvant Chemotherapy Principles & Standard Regimens
11 Chapter 10: Endocrine, HER2-Targeted & Novel Systemic Therapies (Treatment Modalities)
10.1 Endocrine Therapy: SERMs, Aromatase Inhibitors, Ovarian Suppression & SERDs 10.2 HER2-Targeted Monoclonal Antibodies, Antibody-Drug Conjugates & Kinase Inhibitors 10.3 CDK4/6 Inhibitors, PARP Inhibitors & Immune Checkpoint Blockade 10.4 Trop-2 Antibody-Drug Conjugates, PI3K/AKT/mTOR Inhibitors & New Oral SERDs
12 Chapter 11: Specific Conditions & Special Populations (Treatment Modalities)
11.1 Triple-Negative Breast Cancer: Treatment Considerations 11.2 HER2-Positive Breast Cancer: Treatment Considerations 11.3 Inflammatory Breast Cancer & Paget Disease of the Nipple 11.4 Phyllodes Tumors & Breast Angiosarcoma 11.5 Treatment Considerations for Special Populations
13 Chapter 12: Symptom Management & Supportive Care (Nursing Practice)
12.1 Acute Chemotherapy Toxicities, Supportive Regimens & Oncologic Emergencies 12.2 Lymphedema Pathophysiology, ISL Staging & Complete Decongestive Therapy (CDT) 12.3 Musculoskeletal Toxicities, Bone Health & Vasomotor/GSM Relief 12.4 Complementary & Integrative Modalities 12.5 Cancer Rehabilitation: Physical, Occupational & Pelvic Floor Therapy
14 Chapter 13: Oncologic Emergencies (Nursing Practice)
13.1 Oncologic Emergencies I: Spinal Cord Compression, Hypercalcemia, Tamponade & SVC Syndrome 13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
15 Chapter 14: Professional Practice, Clinical Trials & Self-Care (Nursing Practice)
14.1 Professional Practice: Guidelines, Ethics, Legislation, Outreach & Accreditation 14.2 Clinical Trials in Breast Oncology 14.3 Nurse Self-Care: Compassion Fatigue, Burnout, Moral Distress & Substance Use
16 Chapter 15: Psychosocial Dimensions of Care (Psychosocial Dimensions)
15.1 Psychosocial Distress, Coping, Grief & Palliative Care 15.2 Culture, Spirituality, Sexual & Gender Identity, Age & Healthcare Disparities 15.3 Family & Caregiver Dynamics 15.4 Altered Body Image 15.5 Reproductive & Sexual Health
13.2 Oncologic Emergencies II: Hypersensitivity & Anaphylaxis, Sepsis, Pleural Effusion & Thromboembolism
Key Takeaways Explain This Topic AI
Paclitaxel and docetaxel reactions usually occur in the first or second dose within minutes, whereas carboplatin reactions typically appear after several cycles because they are IgE-mediated.
For anaphylaxis, the nurse stops the infusion, calls for help, and gives intramuscular epinephrine (0.01 mg/kg, maximum 0.5 mg in adults) into the anterolateral thigh while supporting airway and circulation.
Surviving Sepsis Campaign guidance calls for blood cultures and broad-spectrum antibiotics within 1 hour for suspected septic shock, with norepinephrine as first-line vasopressor for a mean arterial pressure target of 65 mm Hg.
Breast cancer is the second most common cause of malignant pleural effusion, and recurrent effusions are managed with an indwelling pleural catheter or talc pleurodesis.
ASCO guidance supports direct oral anticoagulants or low-molecular-weight heparin for cancer-associated thrombosis for at least 6 months, with extra caution about bleeding risk and drug interactions.
Last updated: September 2026
- Hypersensitivity Reactions and Anaphylaxis
- High-Risk Agents in Breast Cancer
Agent Mechanism and timing Prevention
Paclitaxel Often related to the Cremophor EL vehicle; usually the first or second infusion, within the first minutes Premedication with dexamethasone, an H1 blocker, and an H2 blocker
Docetaxel Polysorbate 80 vehicle; early in the infusion Dexamethasone premedication (also prevents fluid retention)
Carboplatin IgE-mediated sensitization; typically after several cycles Awareness of cumulative exposure; skin testing or desensitization after a reaction
Trastuzumab, pertuzumab, sacituzumab Infusion-related reactions, mostly with the first dose Premedication per protocol, slower initial rate, observation periods
Distinguish a standard infusion reaction (cytokine-mediated fever, chills, flushing) from anaphylaxis (rapid multisystem involvement: urticaria or angioedema plus respiratory compromise, hypotension, or gastrointestinal symptoms).
Emergency Actions (ONS and Allergy Guidance)
Stop the infusion immediately; keep the IV line open with normal saline using new tubing.
Stay with the patient and call for help (rapid response).
Assess airway, breathing, circulation, and level of consciousness; place the patient supine with legs elevated (or sitting if dyspneic).
For anaphylaxis, give intramuscular epinephrine 0.01 mg/kg (0.3 to 0.5 mg for adults) into the anterolateral thigh ; repeat every 5 to 15 minutes if needed.
Give oxygen and an IV fluid bolus for hypotension.
Adjuncts after epinephrine: H1 and H2 antihistamines, corticosteroids, and bronchodilators for wheezing.
Monitor for biphasic reactions, document, and report.
Rechallenge after a mild taxane reaction is often possible with a slower rate and additional premedication. After anaphylaxis or carboplatin reactions, rechallenge requires allergist input and a desensitization protocol . Emergency equipment and drugs must be at the chairside for every infusion.
Sepsis and Septic Shock
Sepsis is life-threatening organ dysfunction caused by a dysregulated response to infection (Sepsis-3). Septic shock is sepsis requiring vasopressors to keep mean arterial pressure at 65 mm Hg or above with lactate above 2 mmol/L despite adequate fluids. Patients receiving chemotherapy, those with central lines, and those with neutropenia may not show fever or localizing signs.
Recognition clues include new confusion, respiratory rate of 22 or higher, systolic blood pressure of 100 or lower, low urine output, mottled skin, and rising lactate. Early warning scores and nurse-driven sepsis screening speed detection.
Key actions from the Surviving Sepsis Campaign (2021):
Obtain blood cultures before antibiotics without delaying them.
Give broad-spectrum antibiotics within 1 hour for possible septic shock or high likelihood of sepsis.
Give 30 mL/kg of crystalloid within 3 hours for sepsis-induced hypotension or high lactate, reassessing fluid responsiveness.
Measure lactate and repeat it if elevated.
Use norepinephrine as the first-line vasopressor for a MAP target of 65 mm Hg.
Evaluate and remove infected catheters when indicated.
Febrile neutropenia (covered with chemotherapy toxicities) follows the same 1-hour principle.
Malignant Pleural Effusion
Breast cancer is the second most common cause of malignant pleural effusion after lung cancer. Patients report progressive dyspnea, cough, and chest heaviness; examination shows decreased breath sounds and dullness to percussion.
Diagnosis: chest radiograph, ultrasound, or CT; thoracentesis for cytology and symptom relief.
Thoracentesis safety: remove a limited volume (commonly no more than about 1 to 1.5 L at one time) and stop for chest pain, persistent cough, or dyspnea to avoid re-expansion pulmonary edema. Monitor for pneumothorax afterward.
Recurrent effusions: an indwelling pleural catheter allows home drainage and may lead to spontaneous pleurodesis; talc pleurodesis is another option when the lung re-expands.
Nursing teaching for indwelling catheters: sterile drainage technique, drainage schedule (often every other day or as symptoms require), dressing care, and signs of infection or catheter blockage.
Venous Thromboembolism
Cancer raises venous thromboembolism (VTE) risk several-fold. Breast cancer-specific risk factors include tamoxifen, raloxifene, chemotherapy, abemaciclib, central venous catheters, surgery, immobility, and metastatic disease.
Signs: unilateral leg swelling, calf pain, warmth, or redness (DVT); sudden dyspnea, pleuritic chest pain, tachycardia, or hypoxia (PE). Arm swelling on the side of a port may signal catheter-related thrombosis.
Diagnosis: compression duplex ultrasound for DVT; CT pulmonary angiography for PE.
Treatment: ASCO guidance supports direct oral anticoagulants (apixaban, edoxaban, or rivaroxaban) or low-molecular-weight heparin for at least 6 months and while cancer is active. LMWH may be preferred when bleeding risk is high (for example, gastrointestinal or genitourinary lesions) or when drug interactions or absorption are concerns.
Prevention: pharmacologic prophylaxis after major surgery and for hospitalized patients; for ambulatory patients starting chemotherapy with a Khorana score of 2 or higher, prophylaxis with apixaban, rivaroxaban, or LMWH may be offered.
Nursing role: teach warning signs, encourage mobility and hydration, review interactions (strong CYP3A4 and P-glycoprotein inhibitors and inducers affect DOAC levels), monitor for bleeding, and coordinate anticoagulation around procedures.
Triage Summary
Presenting problem Possible emergency Immediate action
Flushing, hives, wheeze, or hypotension during an infusion Hypersensitivity or anaphylaxis Stop infusion, call for help, IM epinephrine for anaphylaxis
Fever, confusion, low blood pressure, or rapid breathing Sepsis or septic shock Cultures and antibiotics within 1 hour, fluids, escalate care
Progressive shortness of breath with dull, quiet lung base Malignant pleural effusion Imaging and thoracentesis
One swollen, painful leg or sudden pleuritic chest pain DVT or pulmonary embolism Urgent evaluation and imaging; anticoagulation
Tumor lysis syndrome and disseminated intravascular coagulation are rare in breast cancer but can occur with bulky, rapidly responding metastatic disease; watch for rising potassium, phosphate, uric acid, and creatinine, or for unexplained bleeding and low platelets.